Limits...
Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke.

Amiri-Nikpour MR, Nazarbaghi S, Ahmadi-Salmasi B, Mokari T, Tahamtan U, Rezaei Y - Neuropsychiatr Dis Treat (2014)

Bottom Line: The median of PI in the right middle cerebral artery was significantly lower in the cerebrolysin group compared with the placebo group on days 30, 60, and 90 (P<0.05).One patient in the cerebrolysin group and two patients in the placebo group died before day 30 (4.3% versus 8.7%).Cerebrolysin can be useful to improve the neurological outcomes and the PI of middle cerebral artery in patients with acute focal ischemic stroke.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Imam Khomeini Hospital, Urmia University of Medical Sciences, Urmia, Iran.

ABSTRACT

Background: Cerebrolysin, a brain-derived neuropeptide, has been shown to improve the neurological outcomes of stroke, but no study has demonstrated its effect on cerebral blood flow. This study aimed to determine the cerebrolysin impact on the neurological outcomes and cerebral blood flow.

Methods: In a randomized, double-blinded, placebo-controlled trial, 46 patients who had acute focal ischemic stroke were randomly assigned into two groups to receive intravenously either 30 mL of cerebrolysin diluted in normal saline daily for 10 days (n=23) or normal saline alone (n=23) adjunct to 100 mg of aspirin daily. All patients were examined using the National Institutes of Health Stroke Scale and transcranial Doppler to measure the mean flow velocity and pulsatility index (PI) of their cerebral arteries at baseline as well as on days 30, 60, and 90.

Results: The patients' mean age was 60±9.7 years, and 51.2% of patients were male. The National Institutes of Health Stroke Scale was significantly lower in the cerebrolysin group compared with the placebo group on day 60 (median 10, interquartile range 9-11, P=0.008) and day 90 (median 11, interquartile range 10-13.5, P=0.001). The median of PI in the right middle cerebral artery was significantly lower in the cerebrolysin group compared with the placebo group on days 30, 60, and 90 (P<0.05). One patient in the cerebrolysin group and two patients in the placebo group died before day 30 (4.3% versus 8.7%).

Conclusion: Cerebrolysin can be useful to improve the neurological outcomes and the PI of middle cerebral artery in patients with acute focal ischemic stroke.

No MeSH data available.


Related in: MedlinePlus

Study flow chart.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4263193&req=5

f1-ndt-10-2299: Study flow chart.

Mentions: Of 98 patients who were assessed for eligibility, 46 patients (46.9% recruitment rate) were assigned into the cerebrolysin (n=23) and placebo (n=23) groups. After receiving treatments, one patient in the cerebrolysin-received group and two patients in the placebo-received group died before day 30 (4.3% versus 8.7%); they were excluded from the final analysis due to lack of measuring their outcomes at 90-day follow-up (Figure 1). The patients’ mean age was 60±9.7 years, and no significant difference was observed between the two groups (P=0.987). Most patients were male (51.2%), and there was no significant difference between the cerebrolysin and placebo groups (P=0.650). Other demographics, including cerebrovascular risk factors and drug histories, are shown in Table 1. The anatomical part of stroke was predominantly located in anterior circulation of brain without significant difference (69.8%, P=0.370).


Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke.

Amiri-Nikpour MR, Nazarbaghi S, Ahmadi-Salmasi B, Mokari T, Tahamtan U, Rezaei Y - Neuropsychiatr Dis Treat (2014)

Study flow chart.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4263193&req=5

f1-ndt-10-2299: Study flow chart.
Mentions: Of 98 patients who were assessed for eligibility, 46 patients (46.9% recruitment rate) were assigned into the cerebrolysin (n=23) and placebo (n=23) groups. After receiving treatments, one patient in the cerebrolysin-received group and two patients in the placebo-received group died before day 30 (4.3% versus 8.7%); they were excluded from the final analysis due to lack of measuring their outcomes at 90-day follow-up (Figure 1). The patients’ mean age was 60±9.7 years, and no significant difference was observed between the two groups (P=0.987). Most patients were male (51.2%), and there was no significant difference between the cerebrolysin and placebo groups (P=0.650). Other demographics, including cerebrovascular risk factors and drug histories, are shown in Table 1. The anatomical part of stroke was predominantly located in anterior circulation of brain without significant difference (69.8%, P=0.370).

Bottom Line: The median of PI in the right middle cerebral artery was significantly lower in the cerebrolysin group compared with the placebo group on days 30, 60, and 90 (P<0.05).One patient in the cerebrolysin group and two patients in the placebo group died before day 30 (4.3% versus 8.7%).Cerebrolysin can be useful to improve the neurological outcomes and the PI of middle cerebral artery in patients with acute focal ischemic stroke.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Imam Khomeini Hospital, Urmia University of Medical Sciences, Urmia, Iran.

ABSTRACT

Background: Cerebrolysin, a brain-derived neuropeptide, has been shown to improve the neurological outcomes of stroke, but no study has demonstrated its effect on cerebral blood flow. This study aimed to determine the cerebrolysin impact on the neurological outcomes and cerebral blood flow.

Methods: In a randomized, double-blinded, placebo-controlled trial, 46 patients who had acute focal ischemic stroke were randomly assigned into two groups to receive intravenously either 30 mL of cerebrolysin diluted in normal saline daily for 10 days (n=23) or normal saline alone (n=23) adjunct to 100 mg of aspirin daily. All patients were examined using the National Institutes of Health Stroke Scale and transcranial Doppler to measure the mean flow velocity and pulsatility index (PI) of their cerebral arteries at baseline as well as on days 30, 60, and 90.

Results: The patients' mean age was 60±9.7 years, and 51.2% of patients were male. The National Institutes of Health Stroke Scale was significantly lower in the cerebrolysin group compared with the placebo group on day 60 (median 10, interquartile range 9-11, P=0.008) and day 90 (median 11, interquartile range 10-13.5, P=0.001). The median of PI in the right middle cerebral artery was significantly lower in the cerebrolysin group compared with the placebo group on days 30, 60, and 90 (P<0.05). One patient in the cerebrolysin group and two patients in the placebo group died before day 30 (4.3% versus 8.7%).

Conclusion: Cerebrolysin can be useful to improve the neurological outcomes and the PI of middle cerebral artery in patients with acute focal ischemic stroke.

No MeSH data available.


Related in: MedlinePlus